1439933-35-3

Upstream product

• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 3959-07-7 4-Bromobenzylamine 
• 954231-79-9 methyl 4-((4-bromobenzyl)amino)-3-nitrobenzoate 
• 1304613-72-6 methyl 3-amino-4-((4-bromobenzyl)amino)benzoate 
• 149-73-5 trimethyl orthoformate 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 26663-77-4 methyl 1H-benzo[d]imidazole-5-carboxylate 

Downstream Products

• 1036499-68-9 1-(4-bromobenzyl)-1H-benzo[d]imidazole-5-carboxylic acid 
• 1439933-36-4 (S)-1-(4-bromobenzyl)-N-(1-(3-isopropylphenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide 
• 1439933-37-5 (S)-N-(1-(3-isopropylphenyl)ethyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-benzo[d]imidazole-5-carboxamide 
• 1439933-38-6 (S)-methyl 3-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)picolinate 
• 1439933-15-9 (S)-3-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)picolinic acid 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.